Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Financial Select Sector SPDR Fund — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Financial Select Sector SPDR Fund trades at $54.76 (market cap $50.06B). The key difference: Financial Select Sector SPDR Fund is far larger — about 4× Halozyme Therapeutics Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Financial Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| HALO | XLF | |
|---|---|---|
Market Cap | $12.58B | $50.06B |
Volume | 2,179,278 | 47,464,120 |
Sector | Health | — |
52-Week High | $115.22 | $58.55 |
52-Week Low | $61.63 | $47.80 |
Typical Hold Time | 1 Days | 104 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLF trades at $54.73, up 1.82% with a bearish technical signal as moving averages and ADX indicators suggest selling pressure. The financial ETF faces sector headwinds with bank stocks lagging the S&P 500 by the widest margin since 1990 despite rising profits. Recent Fed stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
Financial sector exposure benefits from rising interest rates but faces regulatory uncertainty and market underperformance risks. The ETF's concentrated 76-holding portfolio offers targeted financial exposure while competing with broader alternatives. Sector rotation into financials by fund managers in Q2 2026 suggests institutional confidence despite recent relative weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
